United Health Products Applying for Class III Designation for HemoStyp® by Australian TGA

Henderson, Nevada – December 12, 2017 – United Health Products, Inc. (OTCQB: UEEC) United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced it is applying to have HemoStyp designated as a Class III medical device with Australia’s Therapeutics Goods Administration (TGA, counterpart to the U.S. FDA).  Similar to the US FDA Class III application, this will allow for internal surgical use. The company’s Australian TGA consultants believe that UHP has the requisite test data and documentation to obtain rapid approval in Australia, and that HemoStyp® could obtain approval for use in the Australian market within 30 days. 

About TGA 
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. We carry out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard with the aim of ensuring that the Australian community has access, within a reasonable time, to therapeutic advances. https://www.tga.gov.au/about-tga

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com